Vanda Pharmaceuticals (VNDA) Non-Current Assets (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Non-Current Assets of $140.4 million for Q1 2026, down 0.94% sequentially from $141.7 million in Q4 2025, and down 37.35% YoY from $224.0 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Non-Current Assets (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $140.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 37.35% year-over-year to $140.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $745.5 million (down 13.94% YoY) and the FY2025 annual result came in at $141.7 million, down 34.8% from the prior year.
- Non-Current Assets fell to $140.4 million in Q1 2026 per VNDA's latest filing, from $141.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $233.6 million in Q3 2025 and troughed at $105.0 million in Q3 2023.
- A 5-year average of $165.7 million and a median of $141.7 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets jumped 102.53% in 2024, then sank 37.35% in 2026.
- Over 5 years, Non-Current Assets stood at $115.0 million in 2022, then soared by 87.46% to $215.5 million in 2023, then grew by 0.84% to $217.3 million in 2024, then plunged by 34.8% to $141.7 million in 2025, then dropped by 0.94% to $140.4 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $140.4 million, $141.7 million, and $233.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 147.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 147.98 Mn |
| Mar 31, 2026 | 140.36 Mn |
| Dec 31, 2025 | 141.69 Mn |
| Sep 30, 2025 | 233.64 Mn |
| Jun 30, 2025 | 229.83 Mn |
| Mar 31, 2025 | 224.03 Mn |
| Dec 31, 2024 | 217.31 Mn |
| Sep 30, 2024 | 212.73 Mn |
| Jun 30, 2024 | 212.19 Mn |
| Mar 31, 2024 | 213.26 Mn |
| Dec 31, 2023 | 215.49 Mn |
| Sep 30, 2023 | 105.03 Mn |
| Jun 30, 2023 | 108.18 Mn |
| Mar 31, 2023 | 110.83 Mn |
| Dec 31, 2022 | 114.96 Mn |
| Sep 30, 2022 | 114.68 Mn |
| Jun 30, 2022 | 112.21 Mn |
| Mar 31, 2022 | 111.29 Mn |
| Dec 31, 2021 | 115.49 Mn |
| Sep 30, 2021 | 117.96 Mn |